↓ Skip to main content

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial

Overview of attention for article published in Breast Cancer Research, November 2019
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
45 Dimensions

Readers on

mendeley
73 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial
Published in
Breast Cancer Research, November 2019
DOI 10.1186/s13058-019-1215-z
Pubmed ID
Authors

William Jacot, Paul Cottu, Frederique Berger, Coraline Dubot, Laurence Venat-Bouvet, Alain Lortholary, Hugues Bourgeois, Marc Bollet, Veronique Servent, Elisabeth Luporsi, Marc Espié, Severine Guiu, Veronique D’Hondt, Veronique Dieras, Marie-Paule Sablin, Etienne Brain, Souhir Neffati, Jean-Yves Pierga, Francois-Clement Bidard

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 73 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 73 100%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 7 10%
Other 6 8%
Student > Bachelor 6 8%
Student > Master 6 8%
Researcher 6 8%
Other 11 15%
Unknown 31 42%
Readers by discipline Count As %
Medicine and Dentistry 22 30%
Biochemistry, Genetics and Molecular Biology 4 5%
Nursing and Health Professions 3 4%
Pharmacology, Toxicology and Pharmaceutical Science 3 4%
Economics, Econometrics and Finance 2 3%
Other 4 5%
Unknown 35 48%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 December 2019.
All research outputs
#20,667,544
of 25,387,668 outputs
Outputs from Breast Cancer Research
#1,708
of 2,054 outputs
Outputs of similar age
#285,635
of 374,997 outputs
Outputs of similar age from Breast Cancer Research
#20
of 25 outputs
Altmetric has tracked 25,387,668 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,054 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.2. This one is in the 8th percentile – i.e., 8% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 374,997 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 25 others from the same source and published within six weeks on either side of this one. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.